Clinical Trial Update: A Study of YM178 in Patients With Symptomatic Overactive Bladder [Phase 2]

View source ↗

Summary

A Phase 2 study of YM178 for symptomatic overactive bladder conducted by Astellas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• YM178

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 2 | Status: COMPLETED